MediQuest Therapeutics
Topical therapies for inflammatory and infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $3.7m | Early VC | |
| Total Funding | 000k | ||
Related Content
MediQuest Therapeutics, Inc. was a specialty biopharmaceutical company that developed therapeutics for treating inflammatory and infectious diseases. Founded in 2002 and based in Seattle, Washington, the company focused on creating treatments based on its proprietary topical amphiMatrix (TAM) drug delivery technology. This system was designed to deliver active agents through thickened skin and nails to the site of inflammation or infection.
The company's pipeline included clinical-stage products targeting conditions such as Raynaud's phenomenon, nail psoriasis, and actinic keratosis. One of its notable projects was MQX-503, a topical formulation for treating Raynaud's Disease, which showed positive results in a Phase III study by reducing symptom severity with minimal side effects. Over its lifetime, MediQuest Therapeutics raised a total of $22 million in funding over four rounds, with investors including Novo Holdings and Janus Henderson Investors. The company, which was also formerly known as Origen Corporation and Oridigm Corporation, is now listed as out of business.
Keywords: biopharmaceutical, inflammatory diseases, infectious diseases, topical drug delivery, TAM technology, clinical trials, Raynaud's phenomenon, nail psoriasis, actinic keratosis, specialty pharmaceutical, topical therapies, drug development, out of business